Physician profile
Benjamin Barlow
NPI 1699931808
$18,777.73
in general payments reported to CMS, 2019-2025
7 companies · $186 in 2025
The $186 reported for 2025 was more than what 81% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.41 · 2021: $5,166 · 2022: $8,437 · 2023: $4,893 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,850 · Travel and Lodging: $856 · Food and Beverage: $363 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,850.00 |
| Travel and Lodging | $855.79 |
| Food and Beverage | $363.20 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,603.33 | 2021-2022 | |
| Medline Industries LP | $4,892.57 | 2023 | |
| Biomerieux INC | $1,500.00 | 2022 | |
| Biofire Diagnostics, LLC | $1,500.00 | 2021 | |
| Mckesson Medical-Surgical, INC. | $186.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.60 | 2019 | |
| Genentech USA, INC. | $19.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.